Alain Beck
Alain Beck
Centre d'Immunologie Pierre Fabre
Email verificata su pierre-fabre.com
TitoloCitata daAnno
Strategies and challenges for the next generation of therapeutic antibodies
A Beck, T Wurch, C Bailly, N Corvaia
Nature reviews immunology 10 (5), 345-352, 2010
8022010
Strategies and challenges for the next generation of antibody–drug conjugates
A Beck, L Goetsch, C Dumontet, N Corvaïa
Nature reviews Drug discovery 16 (5), 315, 2017
6522017
Characterization of therapeutic antibodies and related products
A Beck, E Wagner-Rousset, D Ayoub, A Van Dorsselaer, ...
Analytical chemistry 85 (2), 715-736, 2013
4192013
A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor …
L Goetsch, A Gonzalez, O Leger, A Beck, PJ Pauwels, JF Haeuw, ...
International journal of cancer 113 (2), 316-328, 2005
2632005
Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins
A Beck, E Wagner-Rousset, MC Bussat, M Lokteff, C Klinguer-Hamour, ...
Current pharmaceutical biotechnology 9 (6), 482-501, 2008
2362008
Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry
A Beck, S Sanglier-Cianférani, A Van Dorsselaer
Analytical chemistry 84 (11), 4637-4646, 2012
2152012
Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody
J Vlasak, MC Bussat, S Wang, E Wagner-Rousset, M Schaefer, ...
Analytical biochemistry 392 (2), 145-154, 2009
1792009
Marketing approval of mogamulizumab: a triumph for glyco-engineering
A Beck, JM Reichert
MAbs 4 (4), 419-425, 2012
1702012
Antibodies to watch in 2014
JM Reichert
MAbs 6 (1), 5-14, 2014
166*2014
Theory and practice of size exclusion chromatography for the analysis of protein aggregates
S Fekete, A Beck, JL Veuthey, D Guillarme
Journal of pharmaceutical and biomedical analysis 101, 161-173, 2014
1582014
The next generation of antibody-drug conjugates comes of age
A Beck, JF Haeuw, T Wurch, L Goetsch, C Bailly, N Corvaia
Discovery medicine 10 (53), 329-339, 2010
1542010
Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells
A Beck, MC Bussat, N Zorn, V Robillard, C Klinguer-Hamour, S Chenu, ...
Journal of chromatography B 819 (2), 203-218, 2005
1372005
Middle-down analysis of monoclonal antibodies with electron transfer dissociation orbitrap fourier transform mass spectrometry
L Fornelli, D Ayoub, K Aizikov, A Beck, YO Tsybin
Analytical chemistry 86 (6), 3005-3012, 2014
1332014
Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry …
D Ayoub, W Jabs, A Resemann, W Evers, C Evans, L Main, C Baessmann, ...
MAbs 5 (5), 699-710, 2013
1292013
Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies
A Beck, JM Reichert
MAbs 3 (5), 415-416, 2011
1282011
Antibody-drug conjugates: present and future
A Beck, JM Reichert
MAbs 6 (1), 15-17, 2014
1232014
Anti-IGF-IR antibodies and uses thereof
L Goetsch, N Corvaia, O Leger, A Duflos, JF Haeuw, A Beck
US Patent 7,241,444, 2007
123*2007
Innovative native MS methodologies for antibody drug conjugate characterization: high resolution native MS and IM-MS for average DAR and DAR distribution assessment
F Debaene, A Bœuf, E Wagner-Rousset, O Colas, D Ayoub, N Corvaïa, ...
Analytical chemistry 86 (21), 10674-10683, 2014
1212014
Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults
UF Power, TN Nguyen, E Rietveld, RL de Swart, J Groen, ...
The Journal of infectious diseases 184 (11), 1456-1460, 2001
1212001
Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry
A Beck, JM Reichert
MAbs 5 (5), 621-623, 2013
1192013
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20